| Bradbury, Penelope A |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
CCTG IND.238A, NCT03847649: A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies |
|
|
| Recruiting | 2 | 60 | Canada | Durvalumab, Prednisone, Tremelimumab | Canadian Cancer Trials Group, AstraZeneca | Cancer | 04/30 | 04/31 | | |
NCT05714891: Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 4 | Canada | JDQ443 | Canadian Cancer Trials Group, Novartis | NSCLC | 08/26 | 03/28 | | |
| luo, xiaoping |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
NCT05353192: A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia |
|
|
| Recruiting | 4 | 38 | RoW | Recombinant human growth hormone | GeneScience Pharmaceuticals Co., Ltd., Children's Hospital of Fudan University, Tongji Hospital, Children's Hospital of Nanjing Medical University, Jiangxi Province Children's Hospital, Chengdu Women's and Children's Central Hospital, Shandong Provincial Hospital, Shengjing Hospital, Shanghai Children's Hospital, Children's Hospital of The Capital Institute of Pediatrics, West China Second University Hospital, Sichuan University | Achondroplasia | 02/25 | 02/25 | | |
NCT05144035: A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants |
|
|
| Recruiting | 4 | 138 | RoW | PEG-rhGH, jintrolong | Tongji Hospital, GeneScience Pharmaceuticals Co., Ltd. | Small for Gestational Age Infant, Growth Hormone Treatment, Cognitive Developmental Disorder | 12/25 | 06/26 | | |
| Completed | 3 | 20 | RoW | Velaglucerase Alfa, VPRIV | Takeda, Takeda | Gaucher Disease | 08/24 | 08/24 | | |
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty |
|
|
| Recruiting | 3 | 93 | US, RoW | Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide | Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd. | Puberty; Precocious, Central | 11/25 | 06/26 | | |
NCT04513171: Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children |
|
|
| Completed | 2/3 | 434 | RoW | Y-shape pegylated somatropin, Norditropin®, Norditropin | Xiamen Amoytop Biotech Co., Ltd., Tongji Hospital | Growth Hormone Deficiency | 06/23 | 07/23 | | |
NCT03255694: A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature |
|
|
| Active, not recruiting | 2 | 360 | RoW | PEG-somatropin, Polyethylene Glycol Recombinant Human Somatropin Injection | GeneScience Pharmaceuticals Co., Ltd., Tongji Hospital, The First Hospital of Jilin University, Affiliated Hospital of Jiangnan University, The First Affiliated Hospital with Nanjing Medical University, Shanghai Children's Hospital, The Children's Hospital of Zhejiang University School of Medicine, Children's Hospital of Fudan University | Dwarfism | 06/30 | 06/30 | | |
| Completed | N/A | 743 | RoW | | Changchun GeneScience Pharmaceutical Co., Ltd., Tongji Hospital | Turner Syndrome | 06/23 | 06/23 | | |
| Recruiting | N/A | 15 | RoW | Nitisinone, Orfadin® | Swedish Orphan Biovitrum | Hereditary Tyrosinemia, Type I | 06/27 | 06/27 | | |
NCT05137301: Performance of the Diagnostic Value of Bone Age Assessment Software Based on Deep Learning in Chinese Children |
|
|
| Recruiting | N/A | 1000 | RoW | X-ray bone age instrument | Tongji Hospital, GeneScience Pharmaceuticals Co., Ltd. | Endocrine Diseases | 12/24 | 12/24 | | |
| Huang, Tao |
NCT05480436: Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population |
|
|
| Recruiting | 4 | 1200 | RoW | coadministration, COVID-19 vaccine, IIV4+PPV23 | China National Biotec Group Company Limited, Hunan Provincial Center for Disease Control and Prevention, Sichuan Center for Disease Control and Prevention, Guizhou Center for Disease Control and Prevention, Xiangya Hospital of Central South University, Beijing Institute of Biological Products Co Ltd., Chengdu Institute of Biological Products Co.,Ltd., Shanghai Institute Of Biological Products | Hemolysis, COVID-19 | 01/23 | 07/23 | | |
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer |
|
|
| Recruiting | 4 | 1072 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast | 12/27 | 07/28 | | |
NCT05091411: Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells) |
|
|
| Recruiting | 3 | 1680 | RoW | Recombinant new coronavirus vaccine (CHO cell) group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Coronavirus Disease 2019 | 11/21 | 12/22 | | |
NCT05107375: Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine |
|
|
| Completed | 3 | 299 | RoW | Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Coronavirus Disease 2019 | 03/22 | 03/22 | | |
NCT05642078: Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine |
|
|
| Completed | 3 | 2550 | RoW | Investigational Vaccine(0.25ml/vial), Investigational Vaccine(0.5ml/vial), Active compared Vaccine | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Prevention of Influenza | 01/24 | 01/24 | | |
NCT06524947: Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) |
|
|
| Recruiting | 3 | 6600 | RoW | quadrivalent recombinant norovirus vaccine (Pichia pastoris), quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Acute Gastroenteropathy Due to Norovirus | 03/27 | 03/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT05109598: Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell) |
|
|
| Completed | 2 | 400 | RoW | Recombinant new coronavirus vaccine (CHO cell) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | COVID-19 | 02/22 | 04/23 | | |
NCT05352867: Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People |
|
|
| Completed | 2 | 420 | RoW | SARS-CoV-2 (LVRNA009) 50μg group, SARS-CoV-2 (LVRNA009) 100μg group, Placebo | AIM Vaccine Co., Ltd., Hunan Provincial Center for Disease Control and Prevention | SARS-CoV-2 | 06/22 | 06/23 | | |
NCT05003466: Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19) |
|
|
| Not yet recruiting | 2 | 480 | RoW | SARS-CoV-2 Vaccine (Vero Cells), Inactivated, Placebo | Shenzhen Kangtai Biological Products Co., LTD, Beijing Minhai Biotechnology Co., Ltd, Hunan Province Centers for Disease Control and Prevention | COVID-19 | 03/23 | 04/23 | | |
NCT05373472: Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older |
|
|
| Completed | 2 | 150 | RoW | COVID-19 mRNA vaccine, Placebo | CanSino Biologics Inc. | COVID-19 | 09/22 | 09/22 | | |
NCT05284812: A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02) |
|
|
| Suspended | 2 | 200 | RoW | Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02), Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Tuberculosis | 06/24 | 12/24 | | |
NCT05198063: ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization |
|
|
| Completed | 1/2 | 300 | RoW | Recombinant novel coronavirus vaccine (CHO cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Prevention of COVID-19 | 08/22 | 12/22 | | |
NCT05148091: The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults |
|
|
| Completed | 1/2 | 478 | RoW | SCTV01C, Adjuvant, SCT-VA02B, Saline | Sinocelltech Ltd. | COVID-19 | 08/23 | 08/23 | | |
NCT05003479: Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19) |
|
|
| Not yet recruiting | 1 | 84 | RoW | SARS-CoV-2 Vaccine (Vero Cells), Inactivated, Placebo | Shenzhen Kangtai Biological Products Co., LTD, Beijing Minhai Biotechnology Co., Ltd, Hunan Province Centers for Disease Control and Prevention | COVID-19 | 09/22 | 10/22 | | |
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors |
|
|
| Active, not recruiting | 1 | 208 | US, RoW | BB-1701 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Locally Advanced/Metastatic HER2 Positive Solid Tumors | 08/24 | 12/24 | | |
NCT05373485: Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older |
|
|
| Completed | 1 | 43 | RoW | COVID-19 mRNA vaccine, Placebo | CanSino Biologics Inc. | COVID-19 | 08/22 | 08/22 | | |
NCT05602480: Phase I Clinical Trial of a Candidate PCV13 in Healthy People |
|
|
| Recruiting | 1 | 264 | RoW | 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, PCV13, Prevnar 13 | Wuhan BravoVax Co., Ltd., Hunan Provincial Center for Disease Control and Prevention, Liaoning Chengda Biotechnology CO., LTD | Pneumococcal Infections | 06/24 | 12/24 | | |
| Dong, Xiaorong |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06280196: A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC |
|
|
| Recruiting | 3 | 676 | RoW | BAT3306, Pembrolizumab Injection, EU-Keytruda®, US-Keytruda®, Pemetrexed, Pemetrexed Fresenius Kabi, Carboplatin, Carboplatin Kabi | Bio-Thera Solutions | Carcinoma, Non-Small-Cell Lung | 07/27 | 10/28 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib |
|
|
| Recruiting | 2 | 54 | RoW | ABSK043 in combination with Firmonertinib | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer With EGFR Mutation | 12/27 | 06/28 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT06144671: GT201 Injection For The Treatment Of Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 18 | RoW | GT201 | Grit Biotechnology | Solid Tumor, Adult | 09/26 | 09/26 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1/2 | 76 | RoW | H002 capsule, H002 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
NCT05367778: Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 176 | RoW | HS-10370 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Advanced Solid Tumor | 05/21 | 12/21 | | |
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
NCT04489862: αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors |
|
|
| Recruiting | 1 | 10 | RoW | αPD1-MSLN-CAR T cells | Wuhan Union Hospital, China, Shanghai Cell Therapy Group Co.,Ltd | Non-small-cell Lung Cancer, Mesothelioma | 06/22 | 12/22 | | |
NCT05025358: A Study of LP-118 in Patients with Advanced Tumors |
|
|
| Active, not recruiting | 1 | 96 | RoW | LP-118 tablet, NWP-4-76 | Guangzhou Lupeng Pharmaceutical Company LTD. | Solid Tumor, Lymphoma, Non-Hodgkin | 01/25 | 12/25 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/25 | 12/25 | | |
NCT05430386: Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1 | 174 | RoW | HS-10241, Almonertinib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 12/23 | 12/23 | | |
| Recruiting | 1 | 31 | US, RoW | AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect | Adlai Nortye Biopharma Co., Ltd. | Advanced Solid Tumor, Advanced Lymphoma | 08/25 | 12/25 | | |
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 164 | US, RoW | ABSK112, EGFR Exon20 inhibitor | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer | 03/27 | 03/28 | | |
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| Li, Guiling |
| Active, not recruiting | 3 | 502 | Europe, Canada, Japan, US, RoW | tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed | Seagen Inc., Genmab | Cervical Cancer | 07/23 | 08/25 | | |
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer |
|
|
| Recruiting | 2 | 58 | RoW | MRG002 | Shanghai Miracogen Inc. | Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 06/22 | 09/22 | | |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 03/25 | 10/25 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. |
|
|
| Recruiting | 2 | 90 | RoW | B013, Paclitaxel, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Platinum-resistant Recurrent Ovarian Cancer | 12/26 | 12/26 | | |
NCT06798207: A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced |
|
|
| Not yet recruiting | 2 | 90 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gynecological Tumors | 05/26 | 11/26 | | |
| Recruiting | 2 | 240 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc. | Solid Tumor | 11/26 | 12/27 | | |
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer |
|
|
| Recruiting | 2 | 460 | RoW | HS-20089 | Hansoh BioMedical R&D Company | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 12/25 | 12/27 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
NCT04718376: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer |
|
|
| Terminated | 1 | 56 | RoW | Mitoxantrone Hydrochloride Liposome, intravenous injection (IV) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Platinum-resistant Ovarian Cancer | 05/23 | 05/23 | | |
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 350 | US, RoW | IMP7068 | Impact Therapeutics, Inc., Covance | Advanced Solid Tumors | 04/23 | 08/23 | | |
NCT04606472: A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 159 | RoW | SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Solid Tumor | 06/25 | 06/25 | | |
NCT05866354: To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies |
|
|
| Completed | 1 | 19 | RoW | Tisotumab Vedotin | Zai Lab (Shanghai) Co., Ltd. | Solid Malignancies | 11/23 | 11/23 | | |
| Recruiting | 1 | 170 | RoW | SPH7485 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumor | 12/27 | 12/27 | | |
| Recruiting | 1 | 216 | RoW | BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection | Bio-Thera Solutions | Advanced Solid Tumors | 12/24 | 12/25 | | |
| Recruiting | 1 | 144 | US, RoW | ADRX-0706 | Adcentrx Therapeutics | Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer | 09/25 | 12/26 | | |
| Cheng, Jing |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
| Soares, Andrey |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
PET-PSMA, NCT05169372: Retrospective Analysis of 68Ga-PSMA-PET in Patients With Prostate Cancer: Experience From Brazil |
|
|
| Terminated | N/A | 12 | RoW | 68Ga-PSMA-PET | Latin American Cooperative Oncology Group, Astellas Pharma Inc | Prostate Cancer | 01/24 | 01/24 | | |
| Liao, Yongde |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Hu, Mu |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| xiaojie, pan |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
